More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling itself to partner Bristol Myers Squibb. Bristol Myers has agreed to buy out its ...

Bristol Myers Squibb (BMS) has agreed to acquire CAR-T specialist Orbital Therapeutics for $1.5bn, adding several RNA-based therapies to the drugmaker’s portfolio. BMS will pay the full amount in cash ...

Bristol Myers Squibb (BMS) has agreed to acquire its longtime cell therapy partner 2seventy bio in a deal valued at $286m. Announced after markets closed on 10 March, the $5-per-share offer represents ...

Bristol Myers Squibb is securing an opportunity to compete in the next generation of cell therapies through the $1.5 billion acquisition of Orbital Therapeutics, a startup with a lead program nearing ...

Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and Abecma, Bristol Myers Squibb is rethinking its operations at the site. BMS ...

Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases Transaction further ...

Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts ...